IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock Has Consensus Price Target of $747.00

Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) have earned an average rating of “Moderate Buy” from the eleven research firms that are presently covering the company, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $747.00.

Several research analysts have recently issued reports on the company. Wall Street Zen downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. KeyCorp assumed coverage on shares of IDEXX Laboratories in a research report on Monday. They issued a “sector weight” rating on the stock. UBS Group increased their price objective on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the company a “neutral” rating in a research note on Wednesday, August 5th. Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday. Finally, Barclays dropped their target price on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a report on Tuesday, August 11th.

Insider Activity

In other news, Director Lawrence D. Kingsley sold 2,203 shares of the stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $532.08, for a total value of $1,172,172.24. Following the sale, the director directly owned 9,568 shares in the company, valued at $5,090,941.44. This represents a 18.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.79% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. J.Safra Asset Management Corp purchased a new stake in shares of IDEXX Laboratories in the second quarter valued at $25,000. SHP Wealth Management acquired a new position in IDEXX Laboratories in the fourth quarter valued at $26,000. Elevation Wealth Partners LLC lifted its position in IDEXX Laboratories by 188.2% during the second quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock worth $26,000 after buying an additional 32 shares during the period. Arlington Trust Co LLC lifted its position in IDEXX Laboratories by 46.3% during the second quarter. Arlington Trust Co LLC now owns 60 shares of the company’s stock worth $32,000 after buying an additional 19 shares during the period. Finally, MV Capital Management Inc. purchased a new position in IDEXX Laboratories during the fourth quarter worth about $46,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $518.00 on Monday. The stock has a fifty day moving average price of $538.96 and a 200 day moving average price of $552.89. The stock has a market cap of $40.81 billion, a PE ratio of 36.43, a P/E/G ratio of 2.77 and a beta of 1.55. IDEXX Laboratories has a 1 year low of $500.61 and a 1 year high of $769.98. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, topping analysts’ consensus estimates of $3.94 by $0.33. The company had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%. IDEXX Laboratories’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same period in the previous year, the business earned $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Sell-side analysts forecast that IDEXX Laboratories will post 14.81 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology and water-testing products and services. The company primarily serves the companion animal veterinary market, helping veterinary practices diagnose and manage diseases through laboratory testing, in-house analyzers, diagnostic kits, imaging systems, software and related consumables.

IDEXX’s companion animal offerings include its IDEXX Reference Laboratories, IDEXX VetLab instruments and software, SNAP rapid tests, and practice-management and data solutions.